- Conditions
- Alzheimer's Disease, Healthy Volunteer
- Interventions
- [11C]RO6924963, [11C]RO6931643, [18F]RO6958948
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 1,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Breast Cancer
- Interventions
- positron emission tomography, radionuclide imaging, fludeoxyglucose F 18
- Procedure · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 120 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cognitive Decline, Alzheimer Disease
- Interventions
- [18F]AV-1451
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Substance Abuse Disorder
- Interventions
- PET scan, fMRI
- Radiation · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 21 Years to 65 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Renal Cell Cancer
- Interventions
- Sunitinib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma
- Interventions
- 18F-Fluciclovine PET-MRI
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
- Interventions
- 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection
- Drug · Procedure
- Lead sponsor
- Thomas Hope
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Parkinson's Disease
- Interventions
- Detailed motor testing, including FoG, in PD subjects
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Normal Physiology
- Interventions
- Methylphenidate Pill, Oral Placebo, Intravenous Placebo, Intravenous methylphenidate
- Drug
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
- Interventions
- 18 F-DOPA
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 1
- Interventions
- 18 F-FP-DTBZ, PET Scanning
- Drug · Radiation
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alzheimer Disease
- Interventions
- flortaucipir F18, Brain PET Scan
- Drug · Procedure
- Lead sponsor
- Avid Radiopharmaceuticals
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
- Interventions
- Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Interventions
- 64Cu-LLP2A, PET/CT
- Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Interventions
- 89 Zr-Df-crefmirlimab
- Drug
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- Ga-68 labeled PSMA-11 PET
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 299 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Colorectal Cancer
- Interventions
- bevacizumab, FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin, ursodiol, RNA analysis, gene expression analysis, polymerase chain reaction, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study, positron emission tomography (PET)
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma
- Interventions
- C11-Sodium Acetate
- Drug
- Lead sponsor
- Phoenix Molecular Imaging
- Other
- Eligibility
- 18 Years to 90 Years · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Cocaine Use Disorder
- Interventions
- Baseline [C-11]NOP-1A PET Scan, Hydrocortisone, Post-hydrocortisone [C-11]NOP-1A PET Scan
- Radiation · Drug
- Lead sponsor
- Rajesh Narendran
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Neuroblastoma
- Interventions
- 124I-Metaiodobenzylguanidine (MIBG) (no-carrier added), 124I-MIBG (carrier added), Positron Emission Tomography (PET) /Computerized tomography (CT)
- Drug · Procedure
- Lead sponsor
- Miguel Pampaloni
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- laboratory biomarker analysis, needle biopsy, positron emission tomography, radionuclide imaging, fludeoxyglucose F 18
- Other · Procedure · Radiation
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Pancreatitis, Graft, Pancreatic Transplant Post-Transplant Dysfunction Rejection
- Interventions
- 18F-fluciclovine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Recurrent Glioblastoma
- Interventions
- [18F]fluoromisonidazole, Bevacizumab, positron emission tomography (PET/CT).
- Biological · Drug · Radiation
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hepatocellular Carcinoma
- Interventions
- FMISO
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama